Answers are grounded in this paper and cite their sources.
Systematic review evaluates neoadjuvant therapy impacts on survival outcomes in patients with NSCLC, suggesting optimal strategies remain unclear.
Immune checkpoint inhibitor (ICI) has improved survival outcomes in patients with resectable non-small cell lung cancer (NSCLC). Recent clinical trials have evaluated several ICI strategies including neoadjuvant-only chemoimmunotherapy, neoadjuvant-adjuvant (perioperative) chemoimmunotherapy, adjuvant-only chemoimmunotherapy, and ICI single- and dual-therapy. However, the optimal perioperative approach remains unclear. As a systematic review, databases were searched to identify eligible randomized controlled trials (RCTs) evaluating perioperative treatment incorporating at least one ICI as perioperative therapy for resectable NSCLC. A random model network meta-analysis was performed. All statistical tests were two-sided. Eleven RCTs with 4,532 patients were included in the analysis. Seven perioperative strategies were compared; however, some were not comparable due to the presence of independent loops. The addition of adjuvant ICI therapy to neoadjuvant chemoimmunotherapy was not associated with improved event-free survival (EFS) (Hazard Ratio [HR] 0.97, 95% confidence interval [95% CI] 0.67-1.41, p = .87) or overall survival (HR 1.17, 95% CI 0.59-2.31, p = .65). When comparing adjuvant-only chemoimmunotherapy to neoadjuvant-only and perioperative chemoimmunotherapy, both neoadjuvant-only and perioperative strategies showed numerically longer OS compared to adjuvant-only chemoimmunotherapy, although the differences were not statistically significant. Regarding safety, the addition of ICI treatment to neoadjuvant chemoimmunotherapy did not significantly increase the incidence of any-grade, grade 3-5, or grade 5 TRAEs. No clear benefit was observed for adding adjuvant ICI therapy to neoadjuvant chemoimmunotherapy. Further research is needed to directly compare neoadjuvant-only vs perioperative chemoimmunotherapy, and to determine the optimal number of cycles and duration of ICI treatment for patients with resectable NSCLC.
No takes yet. Share an insight, caveat, or question.
Aburaki et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: